Ordering Recommendation

Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.


Semi-Quantitative Cell-Based Indirect Fluorescent Antibody




1-8 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Serum separator tube (SST) or plain red

Specimen Preparation

Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.25 mL)

Storage/Transport Temperature


Unacceptable Conditions

Hemolyzed, contaminated, or severely lipemic specimens


Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year

Reference Interval

Test Number
Reference Interval
  CV2.1 Ab IgG CBA-IFA Screen, Serum Less than 1:10

Interpretive Data

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2.1 transfected cell lines for the detection and semiquantification of the CV2.1 IgG antibody.

Compliance Category

Laboratory Developed Test (LDT)


If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.

Hotline History


CPT Codes

86255; if reflexed, add 86256


Component Test Code* Component Chart Name LOINC
2013959 CV2.1 Ab IgG CBA-IFA Screen, Serum 72504-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Cerebellar degeneration
  • Chorea
  • Collapsin response-mediator protein 5
  • Cranial neuropathy
  • CRMP5
  • CV2
  • Myelopathy
  • Peripheral neuropathy
  • Vision loss
CV2.1 Antibody, IgG by CBA-IFA With Reflex to Titer, Serum